Physician profile
Adel A Boutros
NPI 1700952827
$3,081.43
in general payments reported to CMS, 2019-2025
39 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $137 · 2021: $388 · 2022: $647 · 2023: $714 · 2024: $439 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $365.90 | 2021-2025 | Farxiga, Airsupra |
| Vanda Pharmaceuticals INC. | $327.02 | 2021-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $201.54 | 2019-2025 | Trulicity, Kisunla, Humalog |
| Sunovion Pharmaceuticals INC. | $170.70 | 2019-2022 | |
| Astellas Pharma US INC | $160.89 | 2019-2024 | Myrbetriq, Veozah |
| Teva Pharmaceuticals USA, INC. | $138.64 | 2019-2025 | Austedo Xr, Uzedy |
| Glaxosmithkline, LLC. | $132.53 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $125.66 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $124.67 | 2022-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $117.49 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $106.39 | 2021-2022 | |
| Amgen INC. | $104.12 | 2019-2025 | Repatha, Otezla, Repatha |
| Corium, LLC | $76.43 | 2022 | |
| Amarin Pharma, INC. | $76.08 | 2021 | |
| Novo Nordisk INC | $72.76 | 2021-2023 | Ozempic, Rybelsus |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Boutros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.